3 New Drugs Add Decades to Kidney Disease Patients' Lives

For the first time in decades, doctors can offer real hope to the 37 million Americans living with chronic kidney disease.

Three new types of medications are revolutionizing treatment for a condition that was the ninth leading cause of death worldwide in 2023. And researchers believe these drugs could add decades to patients' lives while treating their diabetes, heart problems, and obesity at the same time.

The breakthrough comes after a frustrating dry spell. For years, only one class of drugs could slow kidney disease, and even those worked modestly at best. Scientists spent 15 years testing therapy after therapy, watching each one fail.

Then in 2019, something remarkable happened. When researchers presented results for a diabetes drug called canagliflozin at a medical conference, the audience stood and applauded. The drug had done what no medication could do before: it significantly protected kidneys while reducing deaths and keeping people off dialysis.

That drug belongs to a class called SGLT2 inhibitors, which force excess glucose out through urine while lowering blood pressure in delicate kidney vessels. Two more SGLT2 inhibitors soon proved equally effective, even in patients without diabetes.

The second game changer is the wildly popular Ozempic and similar GLP-1 drugs, originally developed for diabetes. The third is finerenone, which works through yet another pathway to preserve kidney function.

The Ripple Effect

What makes these drugs truly special is that each works differently. Together with the older RAS inhibitors, doctors can now attack kidney disease from four angles simultaneously.

"For the first time there's a realistic prospect of actually stopping kidney disease progression," says Maarten Taal, a kidney specialist at the University of Nottingham in England. He believes the combinations could one day reverse the disease entirely.

The timing couldn't be better. Because kidney patients typically struggle with multiple conditions, these medications treat several problems at once. An Ozempic patient, for example, might see improvements in their kidneys, blood sugar, weight, and heart health from a single prescription.

The most recent trial proved the drugs work across the board, helping even low-risk patients with minimal kidney damage. That means millions more people could benefit from early intervention before their disease progresses.

After decades of watching patients slowly decline toward dialysis and transplants, kidney doctors finally have tools that work. And for patients who've lived with the fear of kidney failure, that changes everything.